Top Markets
#1 Wiki Cat Wiki Cat +47.71%
#2 Siren Siren +35.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.11%
#4 Ribbita by Virtuals Ribbita by Virtuals +20.01%
#5 PulseChain PulseChain +17.72%
#6 Velvet Velvet +17.19%
#7 KUB Coin KUB Coin +17.15%
#8 OpenEden OpenEden +16.37%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +16.32%
#10 aPriori aPriori +16.24%
Coin of the day
Wiki Cat Wiki Cat
Settings
Language
ENGLISH
Currency
USD
Theme
Skye Bioscience, Inc. Skye Bioscience, Inc.

Skye Bioscience, Inc.

SKYE
Rank in Stocks #31149
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on... Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Share Price
$0.38
Market Cap
$13.35M
Change (1 day)
-8.46%
Change (1 year)
-88.79%
Country
US
Trade Skye Bioscience, Inc. (SKYE)

Category

Healthcare
Revenue for Skye Bioscience, Inc. (SKYE)
Revenue in Aug 2026 TTM: 0
According to Skye Bioscience, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Skye Bioscience, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE